1. Home
  2. IMUX vs HOWL Comparison

IMUX vs HOWL Comparison

Compare IMUX & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMUX
  • HOWL
  • Stock Information
  • Founded
  • IMUX 2016
  • HOWL 2017
  • Country
  • IMUX United States
  • HOWL United States
  • Employees
  • IMUX N/A
  • HOWL N/A
  • Industry
  • IMUX Biotechnology: Pharmaceutical Preparations
  • HOWL Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMUX Health Care
  • HOWL Health Care
  • Exchange
  • IMUX Nasdaq
  • HOWL Nasdaq
  • Market Cap
  • IMUX 86.3M
  • HOWL 87.4M
  • IPO Year
  • IMUX N/A
  • HOWL 2021
  • Fundamental
  • Price
  • IMUX $0.94
  • HOWL $1.52
  • Analyst Decision
  • IMUX Strong Buy
  • HOWL Strong Buy
  • Analyst Count
  • IMUX 6
  • HOWL 2
  • Target Price
  • IMUX $12.67
  • HOWL $9.50
  • AVG Volume (30 Days)
  • IMUX 946.7K
  • HOWL 268.9K
  • Earning Date
  • IMUX 02-20-2025
  • HOWL 03-06-2025
  • Dividend Yield
  • IMUX N/A
  • HOWL N/A
  • EPS Growth
  • IMUX N/A
  • HOWL N/A
  • EPS
  • IMUX N/A
  • HOWL N/A
  • Revenue
  • IMUX N/A
  • HOWL $3,386,000.00
  • Revenue This Year
  • IMUX N/A
  • HOWL N/A
  • Revenue Next Year
  • IMUX N/A
  • HOWL $34.17
  • P/E Ratio
  • IMUX N/A
  • HOWL N/A
  • Revenue Growth
  • IMUX N/A
  • HOWL N/A
  • 52 Week Low
  • IMUX $0.92
  • HOWL $1.26
  • 52 Week High
  • IMUX $2.11
  • HOWL $8.19
  • Technical
  • Relative Strength Index (RSI)
  • IMUX 38.85
  • HOWL 57.22
  • Support Level
  • IMUX $0.94
  • HOWL $1.28
  • Resistance Level
  • IMUX $1.02
  • HOWL $1.57
  • Average True Range (ATR)
  • IMUX 0.06
  • HOWL 0.10
  • MACD
  • IMUX 0.00
  • HOWL 0.03
  • Stochastic Oscillator
  • IMUX 13.58
  • HOWL 83.87

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

Share on Social Networks: